Special Issue "Antibody-Drug Conjugates"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (31 July 2013)
Dr. Nazzareno Dimasi
MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
Interests: bispecific antibodies; antibody drug conjugates; Fc-engineered antibodies; cancer therapy; antibody targets; recombinant therapeutic proteins; Fc-fusions; single domain antibodies; bi-functional antibody fusion proteins; drug delivery systems; toxins
Antibody-drug conjugates (ADC) represent an innovative therapeutic application that combines the exquisite properties of monoclonal antibodies, with the potent cell killing activity of cytotoxic small molecule drugs, thus reducing systemic toxicity (often seen with small molecule drugs) while increasing the therapeutic benefits for patients. A special issue of Antibodies, with focus on ADC, welcome manuscripts with examples of early and recent ADC, focusing on choosing the right target, choosing the right antibody, choosing the right cytotoxic small molecule warhead, choosing the right linker, choosing the right site of conjugation on the antibody or antibody fragment, and finally putting the ADC all together. Moreover, manuscript describing novel bio-conjugation strategies, methods to stabilize the ADC, toxicities related to ADC and ADC efficacy in both pre- and clinical settings are also welcome.
Dr. Nazzareno Dimasi
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- antibody-drug conjugates
- small-molecule drugs/warheads
- macromolecule toxins/immunotoxins
- bio-conjugation/antibody modification
- cysteine- and lysine-mediated conjugation
- multifunctional bio-conjugation
- tumor targets/receptors internalization
- site-specific antibody conjugation
- maleimide-based conjugation/maleimide modifications
- stabilized maleimides
- biofunctional linkers
- armed antibodies
- homogeneous conjugation
- cleavable and un-cleavable linkers
- toxicities as relate to antibody-drug conjugates
- efficacy of antibody-drug conjugates
Antibodies 2013, 2(2), 270-305; doi:10.3390/antib2020270
Received: 25 February 2013; in revised form: 3 April 2013 / Accepted: 4 April 2013 / Published: 25 April 2013| PDF Full-text (2166 KB) | HTML Full-text | XML Full-text
Antibodies 2013, 2(1), 113-129; doi:10.3390/antib2010113
Received: 24 December 2012; in revised form: 11 February 2013 / Accepted: 18 February 2013 / Published: 27 February 2013| Cited by 9 | PDF Full-text (336 KB) | HTML Full-text | XML Full-text
Last update: 31 December 2012